Mesothelioma Trials

1. A Phase II Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02784171

Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.

Alberta                                                                                                                                                                          
Edmonton

Ontario                                                                                                                                                                           
Hamilton
London
Toronto
Ottawa

Saskatchewan                                                                                                                                                                 
Regina

Quebec                                                                                                                                                                                                             
Montreal



2. An Open-Label, Multicentre, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody) in Patients With Metastatic Solid Tumours

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02665416

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of RO7009789 in combination with vanucizumab in participants with metastatic solid tumours not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of RO7009789 in this combination. Part II (expansion) is intended to further characterize the safety and clinical activity profile of RO7009789 among indication-specific cohorts.

Ontario
Princess Margaret Hospital, Toronto                                                                                                                                                                 Recruiting 


 

3. Phase I/II Study Evaluating the Infusion of Tumour-Infiltrating Lymphocytes (TILs) and Low-Dose Interleukin-2 (IL-2) Therapy Following a Preparative Regimen of Non-myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients With Malignant Pleural Mesothelioma

 
ClinicalTrials.gov Identifier: NCT02414945

This study is currently recruiting participants.

This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung). Patients will receive an infusion (given by vein) of autologous tumour infiltrating lymphocytes (TILs). TILs are a type of white blood cells that recognizes tumour cells and enter them which causes the tumour cells to break down. Prior to the cell infusion, patients will receive a two drugs cyclophosphamide and fludarabine to prepare the body to receive the TILs. After cell infusion, patients will receive low-dose interleukin-2 therapy. This study will see how safe and useful this regimen is in treating malignant pleural mesothelioma.

Ontario
Toronto



4. Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-dose Computed Tomography

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00188890

Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma). Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers. Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure. We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.

Ontario
Toronto



5. A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00797719

Malignant pleural mesotheliomas (MPMs) are tumours associated with asbestos exposure involving the tissue lining surrounding the lung. Radiation therapy (RT) dramatically reduces the risk of tumour recurrence within the irradiated area (>90%). But patients continue to succumb to MPMs due to the tumour spreading outside the chest cavity. This may be due to tumour cells inadvertently contaminating areas outside the chest cavity during surgery. The study will look at whether giving a short intense course of chest radiation just prior to surgery will sterilized these tumour cells and thus, avoid or reduce contamination of the areas outside the chest cavity. The investigators hypothesize that short neoadjuvant (pre-operative) hemithoracic RT, followed by immediate planned extrapleural pneumonectomy (EPP) (+/- adjuvant chemotherapy) will reduce the risk of intra-operative seeding and reduce the incidence of distant metastatic disease.

Ontario
Toronto



6. Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02385812

Asbestos defines a group of naturally occurring mineral silicate fibers which are easily inhaled, resulting in a variety of diseases of the respiratory system including lung cancer and malignant mesothelioma. Despite some advances in treatment, there has been little impact on overall survival for both lung cancer and mesothelioma in the past 20 years in great part because patients usually present with disease at an advanced and incurable stage. This study aims to develop and implement a low-dose computed tomography (LDCT) screening approach for lung cancer and mesothelioma in asbestos-exposed workers in Alberta.

Alberta
Calgary
Edmonton



7. A Phase1b/2 Study Assessing Safety and Anti-tumour Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumours

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02713529

A multi-centre Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumours.

Ontario
Princess Margaret Hospital, Toronto                                                                                                                                             Recruiting 



8. Developing Optimal Parameters for Hyperpolarized Noble Gas (3He and 129Xe) and Inert Fluorinated Gas Magnetic Resonance Imaging of Lung Disorders

ClinicalTrials.gov Identifier: NCT02748798

This study is ongoing, but not recruiting participants.

The goal of this research is to optimize the MRI system to obtain ideal lung images using Hyperpolarized (HP) Noble and Inert Fluorinated Gases as contrast agents. Lung coils tuned to the frequencies of these gases will be used. This study will take place at TBRHSC in the Cardiorespiratory Department and in the Research MRI facility.
Ontario
Thunder Bay Regional Health Sciences Centre, Thunder Bay

9. A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma

ClinicalTrials.gov Identifier: NCT03710876

This study is currently recruiting participants.

This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. Eligible patients will be randomized 1:1 to either: 1. Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine 2. Control group: Celecoxib followed by Gemcitabine Patients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1. The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM.
Québec 
Québec, Sainte-Foy, Canada, G1V 4G5                                                                                                                                             Recruiting
Institut Universitaire de Cardiologie et de Pneumologie De Quebec
Principal Investigator: Dr Simon Martel, (418) 656-2617,  simon.martel@fmed.ulaval.ca    
Contact: Marie-Eve Morneau, CRC, (418) 656 8711 ext 2690,  Marie-Eve.Morneau@criucpq.ulaval.ca